Molbio Diagnostics IPO Oversubscribed 70x, Lists Monday

Molbio Diagnostics is set to list its IPO on Monday, August 17, on both the NSE and BSE. The offering saw significant demand, oversubscribing by 70.26 times overall.

Subscription Snapshot

Qualified Institutional Buyers (QIBs) led the demand during the subscription period, which ran from August 10 to August 12.

• QIBs: 186.39 times
• Non-Institutional Investors (NIIs): 49.80 times
• Retail investors: 12.96 times

Listing Outlook

The grey market premium (GMP) for Molbio Diagnostics IPO currently stands at ₹125. This suggests a potential listing price of ₹932, marking a 15.49% premium over the ₹807 issue price.

Market experts are forecasting a listing premium between 14-16%. Mahesh M Ojha of Kantilal Chhaganlal Securities advises long-term investors to hold the stock, citing promising growth prospects.

Harshal Dasani, Business Head at INVasset PMS, noted that the company’s post-listing performance hinges on its ability to sustain growth, increase recurring test-kit revenues, and expand internationally.

IPO Details & Utilization

The IPO’s price band was set between ₹768 and ₹807 per share. The issue comprised a fresh issue of shares worth ₹200 crore and an Offer for Sale (OFS) of 91.66 lakh shares, totaling ₹739.70 crore.

Funds from the fresh issue are earmarked for strategic investments and expansion.

• Establishing an R&D facility and center of excellence via subsidiary Bigtec.
• Capital expenditure on new office spaces.
• Acquiring equipment for units in Goa and Visakhapatnam.

Company Profile

Molbio Diagnostics specializes in point-of-care (POC) diagnostics, focusing on accessible, rapid, and affordable healthcare technologies. The company has shown consistent revenue growth, from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26.